Veracyte
Develops molecular tests that guide cancer diagnosis, treatment, and recurrence monitoring.
Something off on this page? Send us feedback.
Profile
Sells molecular cancer tests for diagnosis, prognosis, treatment guidance, and recurrence monitoring through U.S. laboratories, alongside distributed international products and biopharmaceutical services. Decipher Prostate and Afirma generate most revenue, making physician adoption, laboratory throughput, clinical evidence, and payer reimbursement central to the model.
Provides molecular cancer tests used to diagnose disease, estimate prognosis, guide treatment, and monitor recurrence. The U.S. laboratory portfolio includes Decipher Prostate, Afirma for thyroid nodules, Decipher Bladder, Prosigna Breast, and TrueMRD for muscle-invasive bladder cancer; Percepta Nasal Swab is being developed for lung-nodule assessment.
Runs physician-ordered testing through CLIA-certified laboratories in California and Texas, while distributing Prosigna kits through overseas laboratories and hospitals. Whole-transcriptome assays, genomic and clinical datasets, bioinformatics, and evidence generation support product development, payer coverage, and clinical-guideline inclusion; smaller revenue streams include distributed products and biopharmaceutical services.
Most revenue comes from U.S. customers, with Decipher Prostate and Afirma generating the majority. Test volume, physician adoption, payer coverage and reimbursement, laboratory execution, clinical evidence, practice guidelines, and diagnostic regulation shape the business.
Company facts
Key statistics
Year to date +2.2% · Average volume (30d) 1.4M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 4, 2026 | Morgan Stanley | Reiterate | Underweight | $47 | $44 |
| Aug 4, 2026 | Stephens | Target | $55 | ||
| Aug 4, 2026 | Piper Sandler | Reiterate | Overweight | $66 | $54 |
| Aug 3, 2026 | Canaccord Genuity | Reiterate | Hold | $60 | $50 |
| Jul 31, 2026 | Needham | Reiterate | Buy | $57 | $69 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | $0.41 | $0.54 | +31.6% | $144.6M | $150.3M | +4.0% | −22.52% |
| May 5, 2026Q1 FY26 | $0.34 | $0.52 | +52.9% | $130.4M | $139.1M | +6.7% | +24.93% |
| Feb 25, 2026Q4 FY25 | $0.41 | $0.53 | +29.8% | $135.8M | $140.6M | +3.6% | +8.48% |
| Nov 4, 2025Q3 FY25 | $0.32 | $0.51 | +59.4% | $135.8M | $131.9M | −2.9% | +27.46% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $114.5M | $130.2M | $131.9M | $140.6M | $139.1M | $150.3M | |
| Gross profit | $79.5M | $89.8M | $91.3M | $104.7M | $100.6M | $108.6M | |
| Operating income | $2.9M | −$5.3M | $22.9M | $25.9M | $23.8M | $23.0M | |
| Net income | $7.0M | −$980.0K | $19.1M | $41.1M | $28.7M | $25.5M | |
| Diluted EPS | $0.09 | −$0.01 | $0.24 | $0.50 | $0.35 | $0.31 | |
| Gross margin | 69.5% | 69.0% | 69.2% | 74.4% | 72.3% | 72.2% | |
| Operating margin | 2.5% | -4.0% | 17.4% | 18.4% | 17.1% | 15.3% |
Fiscal years (4-quarter sums)FY21 $219.5M · FY22 $296.5M · FY23 $361.1M · FY24 $445.8M · FY25 $517.1M
Revenue by product · Q2 FY26
Revenue by geography · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $485.2M · Total debt $40.1M · Total assets $1.49B · Shareholders' equity $1.39B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 79.79M · Float —
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 13.49M | 16.90% | 13F | Aug 7, 2026 |
| FMR LLC | 7.70M | 9.65% | 13F | Aug 13, 2026 |
| Artisan Partners Limited Partnership | 5.54M | 6.94% | 13F | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 4.72M | 5.91% | 13F | Aug 13, 2026 |
| State Street Corp | 4.70M | 5.89% | 13F | Aug 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 18, 2026 | Karin Eastham | director | −3,729 | $52.89 |
| Jun 4, 2026 | John Leite | officer: Global Chief Commercial Off | −13,975 | $50.07 |
| Jun 4, 2026 | Marc Stapley | director, officer: Chief Executive Officer | −138,051 | $50.12 |
| Jun 4, 2026 | Rebecca Chambers | officer: Chief Financial Officer | −3,561 | $49.73 |
| Jun 4, 2026 | Annie McGuire | officer: EVP, General Counsel | −3,176 | $49.76 |
Peers
- Myriad Genetics
Prostate prognostic testing and oncology-risk overlap
- MDxHealth
Urology-channel rival in prostate molecular diagnostics
- Natera
Primary MRD competitor as TrueMRD scales
- Guardant Health
Liquid-biopsy MRD and therapy-selection pressure
- NeoGenomics
Broad oncology lab competing for cancer-testing workflows
- Biodesix
Lung nodule diagnostics overlapping Percepta
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Veracyte | $44.20 | +2.01% | $3.46B | 31.0 | 23.9 | 6.2 | +15.5% |
| Myriad Genetics | $3.16 | +0.48% | $298.5M | — | — | 0.4 | −10.5% |
| MDxHealth | $0.7000 | −2.87% | $37.0M | — | — | 0.5 | +2.3% |
| Natera | $325.30 | −0.26% | $46.73B | — | — | 17.3 | +37.7% |
| Guardant Health | $161.50 | −0.03% | $21.67B | — | — | 18.3 | +44.3% |
| NeoGenomics | $18.20 | +0.86% | $463.8M | — | 64.9 | 0.6 | +11.2% |
| Biodesix | $26.83 | +0.22% | $218.4M | — | — | 2.1 | +34.2% |
| Median | — | 64.9 | 1.4 | +22.7% |